NCT/Study#
NCT04471844 /
EF-32
EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma
DISEASE GROUP:
Neuro-Oncology
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
